AMPE News and Press, Ampio Pharmaceuticals Inc. From 03/02/22

Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK) Complete analysis of AP-013 data show Ampion reduced pain with statistical significance The U.S. Food and Drug Administration has Confirme...

Ampio Pharmaceuticals, Inc. to Host a Conference Call and Webinar PR Newswire ENGLEWOOD, Colo. , March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therap...

Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes PR Newswire ENGLEWOOD, Colo. , Feb. 10, 2022 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory thera...

Ampio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect Conference PR Newswire ENGLEWOOD, Colo. , Jan. 6, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE), a biopharmaceutical company focused on the advancement of immunolo...

Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders PR Newswire ENGLEWOOD, Colo. , Dec. 16, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapie...

Ampio Pharmaceuticals (NYSE:AMPE) trades 4.1% down premarket after it entered into definitive agreements with institutional investors for the purchase and sale of 25M shares and warrants to purchase 15M shares at a combined purchase price of $0.90/share in a registered direct o...

AMPIO PHARMACEUTICALS ANNOUNCES PRICING OF $22.5 MILLION REGISTERED DIRECT OFFERING PR Newswire ENGLEWOOD, Colo. , Dec. 13, 2021 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immu...

Ampio Pharmaceuticals to Host Business Update Call with Chairman and CEO Mike Martino on Wednesday, Dec. 1 PR Newswire ENGLEWOOD, Colo., Nov. 29, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the ad...

Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael Martino Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael Martino PR Newswire ENGLEWOOD, Colo. , Nov. 2...

Mike Macaluso, Chairman and CEO of Ampio Pharmaceuticals (NYSE:AMPE), is taking a one-year leave of absence from his role to undergo medical treatment. Macaluso's disclosed in October 2021 that he was undergoing medical treatment. Ampio Board member Michael Martino has been named Interim Chai...